MedTrace Logo

Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women

NCT07361926 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2026-01-28

No results posted yet for this study

Summary

This proposed 3-arm randomized study will compare different pharmacy based approaches that include HIV prevention medication (PrEP and PEP), routine STI testing, and preventive antibiotic (doxycycline) for STIs. The study will assess how well these services can be implemented, how acceptable they are to young women, and whether they are cost-effective.

Conditions

  • Sexually Transmitted Infections (Not HIV or Hepatitis)
  • HIV Infections

Interventions

DRUG

doxy-PEP

Antiobiotic for post exposure prophylaxis

DIAGNOSTIC_TEST

Serial STI testing

CT/NG and syphilis testing

DRUG

HIV PEP/PrEP

HIV post and pre exposure prophylaxis

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Washington

    lead OTHER

Principal Investigators

  • Jillian Pintye, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
24 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-06-30
Completion
2030-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07361926 on ClinicalTrials.gov